SCHEMBL30633673

SCHEMBL30633673

CC(=O)c1cn(C(C)C)c2cc(Br)ccc2c1=O

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 2/20 0.40
PDGFRA P16234 1/20 0.39
CDK5 Q00535 1/20 0.39
TYRO3 Q06418 1/20 0.39
LMNA P02545 2/20 0.38
CNR2 P34972 2/20 0.38
HTT P42858 2/20 0.38
ALDH1A1 P00352 1/20 0.38
CNR1 P21554 1/20 0.38
PDE4B Q07343 1/20 0.38
MAOA P21397 1/20 0.37
MAP3K5 Q99683 2/20 0.37
TSHR P16473 1/20 0.35
PDE4A P27815 1/20 0.35
KCNH2 Q12809 1/20 0.35
POLB P06746 1/20 0.35
EGLN1 Q9GZT9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26613882 1.00 NLRP3 (0.40) NLRP3PDGFRACDK5TYRO3LMNA
SCHEMBL23497662 0.89 MYC (0.38) NLRP3LMNAHTTALDH1A1TSHR
SCHEMBL29744413 0.89 MYC (0.38) NLRP3LMNAHTTALDH1A1TSHR
SCHEMBL17576060 0.84 KDM4E (0.43) LMNAHTTALDH1A1MAP3K5POLB
SCHEMBL30633789 0.83 PDGFRA (0.36) NLRP3PDGFRACDK5TYRO3LMNA
SCHEMBL26613860 0.83 PDGFRA (0.36) NLRP3PDGFRACDK5TYRO3LMNA
SCHEMBL1622103 0.82 MYC (0.42) PDGFRACDK5TYRO3LMNACNR2
SCHEMBL29744338 0.82 LMNA (0.61) CDK5LMNAALDH1A1TSHRPOLB
SCHEMBL23497683 0.82 LMNA (0.61) CDK5LMNAALDH1A1TSHRPOLB
SCHEMBL30633681 0.81 LMNA (0.40) NLRP3PDGFRACDK5TYRO3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136586-A1 Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors BEIGENE, LTD. (KY) 2025-05-01 US disclosed
EP-4514797-A1 SUBSTITUTED 7- (PYRIMIDIN-4-YL) QUINOLIN-4 (1H) -ONE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS BeiGene, Ltd. (KY) 2025-03-05 EP disclosed
CN-119053598-A Substituted 7- (pyrimidin-4-yl) quinolin-4 (1H) -one compounds as cyclin dependent kinase inhibitors 百济神州有限公司 2024-11-29 CN disclosed
WO-2023208172-A1 SUBSTITUTED 7- (PYRIMIDIN-4-YL) QUINOLIN-4 (1H) -ONE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS BEIGENE , LTD. (KY) 2023-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136586-A1 Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors CDK4, CDK7, CDK8 NLRP3 3820/4885PDGFRA 882/4885CDK5 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.